Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083759 · ClinicalTrials.gov registry record · Phase 2
Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate
A Phase 2 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 299
- Enrollment target
NCT00083759 is a Phase 2 study that was terminated before completion, run by Biogen. The registered enrollment target is 299 participants.
The verdict
NCT00083759, a Phase 2 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 299 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, tolerability and efficacy of natalizumab in subjects diagnosed with moderate to severe rheumatoid arthritis (RA) receiving concomitant treatment with methotrexate (MTX). It is thought that natalizumab may stop the movement of certain white blood cells, known as lymphocytes, into joint tissue. These cells are thought to cause damage in the joints leading to the symptoms of RA.
Interventions
- DRUG placebo
- DRUG natalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 299 participants |
| Start Date | 2004-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00083759
The ClinicalTrials.gov registry entry for NCT00083759 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 299 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00083759 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00083759 about?
NCT00083759 is a clinical study titled "Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate". The purpose of this study is to determine the safety, tolerability and efficacy of natalizumab in subjects diagnosed with moderate to severe rheumatoid arthritis (RA) receiving concomitant treatment with methotrexate (MTX). It is thought that natalizumab may stop the movement of certain white blood ...
What is the current status of trial NCT00083759?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 299 participants. The study started on 2004-05.
What interventions are being tested in trial NCT00083759?
The interventions under investigation include: placebo (DRUG), natalizumab (DRUG).
Who is sponsoring clinical trial NCT00083759?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.